Earnings ·
Capricor reports $40.7M net loss in Q2 2026 as FDA panel votes against Deramiocel for Duchenne muscular dystrophy
CAPRCapricor Therapeutics, Inc.
Capricor Therapeutics reported second quarter 2026 financial results on August 13, 2026. The company posted a net loss of approximately $40.7 million, or $0.70 per share, compared to a $25.9 million loss in the prior year period. Total operating expenses rose to $42.9 million from $27.7 million, driven by increased research and development costs. Cash, cash equivalents, and marketable securities stood at approximately $238 million as of June 30, 2026. The filing provided a corporate update noting that the FDA Advisory Committee voted 3 to 9 against Deramiocel for cardiomyopathy in Duchenne muscular dystrophy, though it was not asked to vote on the primary upper limb endpoint which achieved statistical significance (p=0.029). The company also disclosed an FDA BIMO inspection Form 483 and a contractual dispute with NS Pharma pending arbitration. Capricor Therapeutics is a biotechnology company developing cell and exosome-based therapeutics for rare diseases.